JPWO2021159092A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021159092A5
JPWO2021159092A5 JP2022547874A JP2022547874A JPWO2021159092A5 JP WO2021159092 A5 JPWO2021159092 A5 JP WO2021159092A5 JP 2022547874 A JP2022547874 A JP 2022547874A JP 2022547874 A JP2022547874 A JP 2022547874A JP WO2021159092 A5 JPWO2021159092 A5 JP WO2021159092A5
Authority
JP
Japan
Prior art keywords
individual
gaa
use according
oligosaccharide
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022547874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512783A5 (https=
JP2023512783A (ja
JP7804582B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017113 external-priority patent/WO2021159092A1/en
Publication of JP2023512783A publication Critical patent/JP2023512783A/ja
Publication of JP2023512783A5 publication Critical patent/JP2023512783A5/ja
Publication of JPWO2021159092A5 publication Critical patent/JPWO2021159092A5/ja
Priority to JP2025138630A priority Critical patent/JP2025166240A/ja
Application granted granted Critical
Publication of JP7804582B2 publication Critical patent/JP7804582B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022547874A 2020-02-08 2021-02-08 ポンペ病を処置するための組成物および方法 Active JP7804582B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025138630A JP2025166240A (ja) 2020-02-08 2025-08-22 ポンペ病を処置するための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062971930P 2020-02-08 2020-02-08
US62/971,930 2020-02-08
US202063115975P 2020-11-19 2020-11-19
US63/115,975 2020-11-19
PCT/US2021/017113 WO2021159092A1 (en) 2020-02-08 2021-02-08 Compositions and methods for treating pompe disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025138630A Division JP2025166240A (ja) 2020-02-08 2025-08-22 ポンペ病を処置するための組成物および方法

Publications (4)

Publication Number Publication Date
JP2023512783A JP2023512783A (ja) 2023-03-29
JP2023512783A5 JP2023512783A5 (https=) 2024-02-16
JPWO2021159092A5 true JPWO2021159092A5 (https=) 2024-02-16
JP7804582B2 JP7804582B2 (ja) 2026-01-22

Family

ID=74853758

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547874A Active JP7804582B2 (ja) 2020-02-08 2021-02-08 ポンペ病を処置するための組成物および方法
JP2025138630A Pending JP2025166240A (ja) 2020-02-08 2025-08-22 ポンペ病を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025138630A Pending JP2025166240A (ja) 2020-02-08 2025-08-22 ポンペ病を処置するための組成物および方法

Country Status (12)

Country Link
US (2) US12251430B2 (https=)
EP (1) EP4100120A1 (https=)
JP (2) JP7804582B2 (https=)
KR (1) KR20220139936A (https=)
CN (1) CN115715218A (https=)
AU (1) AU2021216055A1 (https=)
BR (1) BR112022015505A2 (https=)
CA (1) CA3167091A1 (https=)
IL (1) IL295415A (https=)
MX (1) MX2022009753A (https=)
WO (1) WO2021159092A1 (https=)
ZA (1) ZA202209925B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021216055A1 (en) 2020-02-08 2022-09-29 Genzyme Corporation Compositions and methods for treating pompe disease
MX2022016019A (es) 2020-06-14 2023-04-10 Genzyme Corp Composiciones y metodos para el tratamiento de enfermedad de pompe de inicio tardio.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
SI2457920T1 (en) 2007-01-18 2018-02-28 Genzyme Corporation Oligosaccharides containing the amino acid group and their conjugates
CA3040973A1 (en) * 2008-12-16 2010-07-01 Genzyme Corporation Oligosaccharide-protein conjugates
CN110124039A (zh) 2011-05-16 2019-08-16 建新公司 使用甲氨蝶呤诱导免疫耐受性
US10172924B2 (en) * 2015-03-19 2019-01-08 Translate Bio, Inc. MRNA therapy for pompe disease
KR102510941B1 (ko) * 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
AU2021216055A1 (en) 2020-02-08 2022-09-29 Genzyme Corporation Compositions and methods for treating pompe disease

Similar Documents

Publication Publication Date Title
RU2626512C2 (ru) Концентрированные белковые фармацевтические составы и их применение
Ryan Pemphigus: a 20-year survey of experience with 70 cases
Bergström et al. The effect of thoracic duct lymph drainage in myasthenia gravis
Tanner et al. Growth response of 26 children with short stature given human growth hormone
Fudenberg Are autoimmune diseases immunologic deficiency states?
BR112020001101A2 (pt) composição farmacêutica do complexo de proteína il-15 e usos da mesma
JPS63502591A (ja) リユ−マチ様関節炎の治療のための方法と物質
JPH05508636A (ja) 免疫システム機能不全に関連する障害の予防及び治療のための免疫システム安定剤
CN113244380B (zh) 一种温度敏感型凝胶损伤修复制剂及其应用
Levine et al. Orbital infusion of steroids in the rabbit
Feldman et al. Promizole in Tuberculosis: The Effect on Previously Established Tuberculosis of Guinea Pigs of 4, 2'-Diaminophenyl-5'-Thiazolylsulfone (Promizole)
CN120514848B (zh) 一种cd19抗体药物制剂
JPWO2021159092A5 (https=)
Kay et al. Paraneoplastic opsoclonus-myoclonus in Hodgkin's disease
FRENCH et al. Pheochromocytoma with shock, marked leukocytosis, and unusual electrocardiograms. Case report and review of the literature
Ziai et al. Treatment of central diabetes insipidus in adults and children with desmopressin: A synthetic analogue of vasopressin
Yuceoglu et al. The glomerulopathy of congenital syphilis: a curable immune-deposit disease
Cleghorn et al. The treatment of Addison's disease by a synthetic adrenal cortical hormone (desoxycorticosterone acetate)
BR112020003951A2 (pt) métodos para tratar doenças relacionadas a tnf
RU2137477C1 (ru) Способ лечения заболеваний, характеризующихся аутоиммунной агрессией
Farah et al. Bacterial meningitis associated with infliximab
LAVAL Use of hydrocortisone (hydrocortone) acetate in ophthalmology
CZ274796A3 (en) Application of trophoblastic beta-i-glucoprotein for preparing pharmaceutical preparation and pharmaceutical composition containing thereof
US20250230238A1 (en) Methods and compositions for treating systemic lupus erythematous (sle)
WO2024026388A1 (en) Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein